Public Interest Registry Unveils Winners of 6th Annual .ORG Impact Awards at DC Ceremony Hosted by Emmy Winner Alan Cumming
Yellow Boat of Hope Foundation named 2024 .ORG of the Year, selected from over 1,700 applicants from more than 87 countries WASHINGTON, Oct. 9, 2024 /PRNewswire/ -- Public Interest Registry (PIR), the people behind the .ORG domain, announced the winners of the .ORG Impact Awards, an annual celebration recognizing and rewarding outstanding...
SERVING MORE THAN LOOKS: MAYBELLINE NEW YORK ANNOUNCES NAOMI OSAKA AS THE BRAND’S FIRST BRAVE TOGETHER AMBASSADOR
The four-time Grand Slam tennis champion and mental health advocate teams up with Maybelline New York for World Mental Health Day to amplify the Brave Together program NEW YORK, Oct. 9, 2024 /PRNewswire/ -- In honor of World Mental Health Day on October 10, Maybelline New York is maximizing its mental...
Baird Medical Lists in the U.S. on the Nasdaq Exchange
Company Rings Opening Bell to Celebrate Closure of Business Combination and Begins Journey as a Public Company; Shares trade under "BDMD" Ticker FORT MILL, S.C., Oct. 9, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China which has recently expanded into...
ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine
Implantable Neuromodulation System Shows Early Promise in Improving Patient Quality of Life by Reducing Monthly Headache Days and Severity of Migraine Attacks MINNEAPOLIS, Oct. 9, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage medical device company developing neurostimulation therapies for chronic migraine patients, today announced the closing of a $66 million Series...
International Collaboration Addresses Rising Cancer Rates in South America
National Comprehensive Cancer Network and Latin American Cooperative Oncology Group to publish cancer treatment guidelines tailored for Brazil. PLYMOUTH MEETING, Pa., Oct. 9, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—announces a renewed collaboration with the Latin American Cooperative Oncology Group (LACOG)...
Nona Biosciences Enters Strategic Collaboration with OverT Bio to Advance Next-Generation Cell Therapies for Solid Tumors
CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a strategic collaboration with OverT Bio, a New York-based biotechnology company. The collaboration will focus on developing next-generation cell therapies for solid tumors by leveraging Nona's proprietary fully human HCAb Harbour...
New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts
Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead of future pandemics, released its Antiviral Clinical and Preclinical...
Spring Growth Spurt, Witsbb Vitamin D for Babies Popular at Leading Australian Pharmacy Chains
SYDNEY, Oct. 9, 2024 /PRNewswire/ -- Should newborn babies supplement with vitamin D? How should vitamin D be supplemented? As global consumers' health awareness significantly increases, the demand for nutritional supplements is showing trends towards refinement, diversification, and personalization. One concern for many new mothers is vitamin D supplementation. Recently, in several well-known pharmacy chains in Australia, a "hypoallergenic"...
Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding
OSAKA, Japan, Oct. 9, 2024 /PRNewswire/ -- Alpha Fusion, Inc. (CEO: Sunao Fujioka, headquartered in Kita-ku, Osaka), has raised a total of ¥1.02 billion through a Series B funding round. The round was led by SBI Investment Co., Ltd. and OSAKA University Venture Capital, with participation from several new investors. This funding...
The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.
NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights, for the treatment of the patients with advanced extrapulmonary neuroendocrine carcinoma...
